Product & Technology

Continuous process, not batch

A continuous fermentation and purification line that runs for months at steady state rather than in discrete campaigns: materially higher throughput per litre of installed capacity and far lower capital per kilogram than batch production.

Proprietary strain library

An expression-strain library tuned per target protein, held as trade secret rather than published. Yield per litre improves with every campaign, and that run history is the part a competitor cannot copy from a patent.

Patent-pending process families

Continuous-production and downstream-purification families filed via PCT. Patent-pending, not yet granted. The filings cover the process; the strain library stays a trade secret.

Cosmetics-first go-to-market

Cosmetic-grade actives reach revenue on a shorter qualification cycle than food applications, giving a fast, high-margin beachhead while food-enzyme dossiers work through the longer EU authorisation route in parallel.

Outputs

Now: Specialty actives today: functional proteins and high-value enzymes

Next: Broader catalogue from 2028+, plus licensed production of the same molecules

Reactor scale

Now: 500 L pilot line, continuous operation validated

Next: 2,000 L from 2026, 5,000 L from 2028, then a multi-site network

Strain system

Now: Proprietary expression strains per target protein, non-GMO host where required

Next: Tuned expression at scale and shared platform strains for licensees

Cost & scale

Now: ~€180/kg at pilot scale

Next: Toward <€60/kg at industrial scale, the point where licensing becomes the larger engine